Table 2.
Anticancer effects of samples against A-375 and MDA-MB-468
| Samples | A-375 | MDA-MB-468 | ||||
|---|---|---|---|---|---|---|
| LCL* | IC50* | UCL* | LCL | IC50 | UCL | |
| limonene | 176.18 | 246.05 | 343.62 | 1636.44 | 2118.94 | 2743.71 |
| LimChiNPsa | 13.53 | 30.24 | 67.58 | 498.29 | 650.70 | 849.72 |
| CAEOb | 4832.01 | 10,564.00 | 23,095.00 | 781.41 | 2037.53 | 5312.86 |
| CAChiNPsc | 15.66 | 55.00 | 193.16 | 144.20 | 240.44 | 400.92 |
| CLEOd | 0.49 | 10.54 | 228.46 | 57.41 | 137.03 | 327.06 |
| CLChiNPse | 3.270 | 0.124 | 0.05 | 10.41 | 40.32 | 156.14 |
| CSEOf | 0.01 | 0.02 | 0.03 | 139.97 | 168.00 | 201.65 |
| CSChiNPsg | 0.02 | 0.03 | 0.05 | 2.74 | 23.65 | 204.43 |
a chitosan nanoparticles containing limonene, b C. aurantium EO, c chitosan nanoparticles containing C. aurantium EO, d C. limon EO, e chitosan nanoparticles containing C. limon EO, f C. sinensis EO, chitosan nanoparticles C. sinensis EO
* The half-maximal inhibitory concentration or IC50 (μg/mL) with lower and upper confidence limits; LCL and UCL